CASE REPORT
Thrombosis of the lower right limb in an 11-year-old boy – the first manifestation of systemic lupus erythematosus triggered by SARS-CoV-2 infection
 
More details
Hide details
1
Poznań University of Medical Sciences, Poznań, Poland
 
 
Submission date: 2023-07-13
 
 
Final revision date: 2024-02-06
 
 
Acceptance date: 2024-02-08
 
 
Publication date: 2024-06-27
 
 
Corresponding author
Karolina Frąckowiak
Karolina Frąckowiak, Poznań University of Medical Sciences, Poznań, Poland
 
 
Pediatr Pol 2024;99(2):175-177
 
KEYWORDS
TOPICS
ABSTRACT
The case report describes an 11-year old boy with sudden onset lower right limb thrombosis, hypertension and nephritic syndrome. Laboratory findings revealed positive results of anti-ANA, anti-dsDNA, lupus anticoagulant and COVID-19 IgG antibodies. Vascular ultrasound and computed tomography detected active thrombosis of the right popliteal vein. Kidney biopsy confirmed fourth class lupus nephritis. The patient responded well to a combination of steroids, cyclophosphamide, hydroxychloroquine, rituximab, alteplase, heparin and amlodipine, with the resolution of thrombosis and nephritic syndrome, stabilization of blood pressure and improvement in laboratory findings. The case highlights the importance of prompt diagnosis and appropriate treatment of systematic lupus erythematosus with vein thrombosis and lupus nephritis in children, particularly in male patients. Overall, this case emphasizes the possibility of virus triggering factors in systematic lupus erythematosus and the importance of regular check-ups, monitoring of symptoms in preventing complications and improving the long-term outlook for patients with systemic lupus erythematosus.
REFERENCES (13)
1.
Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012; 64: 797-808.
 
2.
Appenzeller S, Souza FH, Wagner Silva de Souza A, Costallat LT. Predictors of clinical outcome in a cohort of SLE patients with renal involvement: role of VEGF and angiogenic factors. Lupus 2017; 26: 1016-1025.
 
3.
Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-2557.
 
4.
Anders HJ, Saxena R, Zhao MH. Paradoxical effects of immunosuppressive therapies and autoimmune kidney diseases. Nat Rev Nephrol 2018; 14: 256-276.
 
5.
Pennesi M, Benvenuto S. Lupus nephritis in children: novel perspectives. Medicina (Kaunas) 2023; 59: 1841.
 
6.
Eleftheriou D, Brogan PA, Dillon MJ. ANCA-associated vasculitis in childhood: recent advances. Curr Op Rheumatol 2006; 18: 568-573.
 
7.
Driest KD, Sturm MS, O’Brien SH, et al. Factors associated with thrombosis in pediatric patients with systemic lupus erythematosus. Lupus 2016; 25: 749-753.
 
8.
Soybilgic A, Avcin T. Pediatric APS: state of the Art. Curr Rheumatol Rep 2020; 22: 9.
 
9.
Bernstein ML, Salusinsky-Sternbach M, Bellefleur M, Esseltine DW. Thrombotic and hemorrhagic complications in children with the lupus anticoagulant. Am J Dis Child 1984; 138: 1132-1135.
 
10.
Andrew M, David M, Adams M, Ali K, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-1257.
 
11.
Rodrıguez Y, Novelli L, Rojas M, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun 2020; 114: 102506.
 
12.
Jimenez-Santana L, Sanchez-Alonso F. Lupus nephritis: an overview of recent findings. Autoimmune Rev 2019; 18: 706-712.
 
13.
Johnson AE, Gordon C. Understanding and managing lupus nephritis: an update for clinicians. Nat Rev Nephrol 2017; 13: 329-340.
 
Journals System - logo
Scroll to top